2 Biotech Stocks Charging Up the Charts

CymaBay Therapeutics reported upbeat data on its liver disease drug

Managing Editor
Apr 11, 2018 at 10:05 AM
facebook twitter linkedin

Two biotech stocks are making big moves higher this morning, defying the broad-market headwinds related to geopolitical tensions in Syria. Inovio Pharmaceuticals Inc (NASDAQ:INO) scored a critical partnership, while CymaBay Therapeutics Inc (NASDAQ:CBAY) reported upbeat data on its liver disease drug. 

INO Stock Could Benefit From Short Squeeze

The Coalition for Epidemic Preparedness Innovations (CEPI) will award Inovio Pharmaceuticals up to $56 million to advance its DNA vaccines for Lassa fever and MERS. As a result, INO stock is up 3.9% to trade at $4.94, and has rallied 30% from its four-year low of $3.76 on Feb. 9.  However, the shares are still staring up at their 160-day and 200-day moving averages, which have rejected rebound attempts since a bear gap in July 2017.  

A short squeeze is helping fuel the drug stock's rally. Short interest fell by 3.3% during the last reporting period, but the 10.53 million shares sold short still represents more than 12% of INO's total available float. At the equity's average daily trading volume, it would take over a week for the shorts to cover their bearish bets.

CBAY Stock Eyes Best Day Since July

CymaBay Therapeutics stock is up 15.8% to trade at $13.98, on track for its best day since July 2017, after the drugmaker reported a positive mid-stage study update on its liver disease drug, seladelpar. As such, Leerink upped its price target on the equity to $20 from $16 -- representing a premium of 43% to CBAY's current price.

The drug stock touched a record high of $15.59 on March 5, but subsequently pulled back to its 100-day moving average. Today, though, CBAY is set to top its 10- and 20-day trendlines for the first time in more than a month, and sports a year-over-year gain of 233%.

Amid the stock's recent dip, short sellers have piled on. Short interest increased by 11% during the past two reporting periods, to 2.5 million shares. This represents a healthy 8% of CBAY's total available float.

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners